You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



ABCs of GEP-NETs: Overview of Neuroendocrine Tumors

  • Authors: Jean-Yves Scoazec, MD; Raj Srirajaskanthan, MD, FRCP; Jonathan Strosberg, MD
  • CME / ABIM MOC Released: 12/7/2020
  • Valid for credit through: 12/7/2021
Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, gastroenterologists, and pathologists, as well as endocrinologists, radiologists, and nuclear medicine specialists.

The goal of this activity is to provide foundational education on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to better equip community physicians for their management throughout the course of the patient journey. 

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Characteristics of GEP-NETs
    • Testing methodologies used to diagnose and monitor GEP-NETs
    • Guidelines for the management of GEP-NETs


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Jean-Yves Scoazec, MD

    Department Head
    Laboratory Medicine and Pathology
    Gustave Roussy Cancer Center
    Villejuif, France


    Disclosure: Jean-Yves Scoazec, MD, has disclosed no relevant financial relationships.

  • Raj Srirajaskanthan, MD, FRCP

    Consultant Gastroenterologist
    King's College Hospital
    London, United Kingdom


    Disclosure: Raj Srirajaskanthan, MD, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AAA (Advanced Accelerator Applications); Ipsen Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: AAA; Ipsen

  • Jonathan Strosberg, MD

    Professor, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida


    Disclosure: Jonathan Strosberg, MD, has disclosed the following relevant financial relationships:
    Serve(d) as a consultant for: Novartis
    Serve(d) as a speaker or a member of a speakers bureau for: Ipsen; Lexicon


  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC


    Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


ABCs of GEP-NETs: Overview of Neuroendocrine Tumors

Authors: Jean-Yves Scoazec, MD; Raj Srirajaskanthan, MD, FRCP; Jonathan Strosberg, MDFaculty and Disclosures

CME / ABIM MOC Released: 12/7/2020

Valid for credit through: 12/7/2021


111In = indium-111
177Lu = lutetium-177
5-HIAA = 5-hydroxyindoleacetic acid
68Ga = gallium-68
90Y = yttrium-90
AJCC = American Joint Committee on Cancer
ATRX = α-thalassemia mental retardation syndrome
CDKN1B = cyclin-dependent kinase inhibitor 1B
CDX2 = caudal type homeobox 2
CgA = chromogranin A
CT = computed tomography
DAXX = death domain-associated protein
EUS = endoscopic ultrasound
GEP = gastroenteropancreatic
GEP-NET = gastroenteropancreatic neuroendocrine tumor
GI = gastrointestinal
GI-NET = gastrointestinal neuroendocrine tumor
INSM1 = insulinoma-associated protein 1
ISL1 = insulin gene enhancer protein 1
LAR = long acting release
MEN-1 = multiple endocrine neoplasia type 1
MGMT = O-6-methylguanine-DNA methyltransferase
mPFS = median progression-free survival
MRI = magnetic resonance imaging
mTOR = mammalian target of rapamycin
NCCN = National Comprehensive Cancer Network
NEC = neuroendocrine carcinoma
NEN = neuroendocrine neoplasm
NET = neuroendocrine tumor
ORR = objective response rate
OS = overall survival
PDX1 = insulin promoter factor 1
PET = positron emission tomography
PFS = progression-free survival
pNEC = pancreatic neuroendocrine carcinoma
pNET = pancreatic neuroendocrine tumor
PRRT = peptide receptor radionuclide therapy
RB1 = retinoblastoma protein
SEER = Surveillance, Epidemiology, and End Results
SMAD4 = mothers against decapentaplegic homolog 4
SRS = somatostatin receptor scintigraphy
SSA = somatostatin analogue
SSTR = somatostatin receptor
SSTR2 = somatostatin receptor 2
TNM = tumor, node, metastasis
TP53 = tumor protein p53
TSC1 = tuberous sclerosis 1
TSC2 = tuberous sclerosis 2
TTP = time to progression
UICC = Union for International Cancer Control
VHL = Von Hippel Lindau syndrome
VIP = vasoactive intestinal peptide
WHO = World Health Organization

« Return to: ABCs of GEP-NETs: Overview of Neuroendocrine Tumors
  • Print